Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Methodology, biology and clinical applications of human mesenchymal stem cells.

Camassola M., de Macedo Braga LM., Chagastelles PC., Nardi NB.

Clinical Trial on Immune Modulation, Autoimmune Research, published in Methods Mol Biol (2012) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Methods Mol Biol (2012)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
22610579
DOI
10.1007/978-1-61779-815-3_30

Abstract (original English)

Stem cells are known by their capacity of self-renewal and differentiation into at least one specialized cell type. Mesenchymal stem cells (MSCs) were isolated initially from bone marrow but are now known to exist in any vascularized organ or tissue in adults. MSCs have a great therapeutic potential, due to their ability to migrate to sites of tissue injury and secrete trophic factors that hasten endogenous repair. They have also been shown to present immunosuppressive properties that may be used in the treatment of autoimmune or graft-versus-host diseases. Clinical trials employing MSCs show that the therapy is safe, but the efficiency needs to be in tested in phase III and IV studies. We describe here protocols for the isolation of human MSCs from human bone marrow and adipose tissue. The safe use of these cells demand a thorough in vitro characterization, as described in protocols of immunophenotyping by flow cytometry and analysis of their capacity to differentiate into adipogenic, osteogenic, and chondrogenic lineages.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Adipose TissueBone Marrow CellsCell SeparationClinical Trials as TopicFlow CytometryHumansImmunophenotypingMesenchymal Stem Cell TransplantationMesenchymal Stem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research